Department of Immunohematology and Blood Transfusion, Leiden University Medical Center PO Box 9600, 2300 RC Leiden, the Netherlands.
Haematologica. 2010 Jul;95(7):1061-7. doi: 10.3324/haematol.2009.016691. Epub 2010 Jan 15.
Flt3-ligand is a cytokine that induces relatively slow mobilization of hematopoietic cells in animals and humans in vivo. This provides a time-frame to study hematopoietic stem and progenitor cell migration kinetics in detail.
Mice were injected with Flt3-ligand (10 microg/day, intraperitoneally) for 3, 5, 7 and 10 days. Mobilization of hematopoietic stem and progenitor cells was studied using colony-forming-unit granulocyte/monocyte and cobblestone-area-forming-cell assays. The radioprotective capacity of mobilized peripheral blood mononuclear cells was studied by transplantation of 1.5 x 10(6) Flt3-ligand-mobilized peripheral blood mononuclear cells into lethally irradiated (9.5 Gy) recipients.
Hematopoietic progenitor cell mobilization was detected from day 3 onwards and prolonged administration of Flt3-ligand produced a steady increase in mobilized progenitor cells. Compared to Flt3-ligand administration for 5 days, the administration of Flt3-ligand for 10 days led to a 5.5-fold increase in cobblestone-area-forming cells at week 4 and a 5.0-fold increase at week 5. Furthermore, transplantation of peripheral blood mononuclear cells mobilized by 5 days of Flt3-ligand administration did not radioprotect lethally irradiated recipients, whereas peripheral blood mononuclear cells mobilized by 10 days of Flt3-Ligand administration did provide 100% radioprotection of the recipients with significant multilineage donor chimerism. Compared to the administration of Flt3-ligand or interleukin-8 alone, co-administration of interleukin-8 and Flt3-ligand led to synergistic enhancement of hematopoietic stem and progenitor cell mobilization on days 3 and 5.
These results indicate that hematopoietic stem and progenitor cells show different mobilization kinetics in response to Flt3-ligand, resulting in preferential mobilization of hematopoietic progenitor cells at day 5, followed by hematopoietic stem cell mobilization at day 10.
Flt3 配体是一种细胞因子,它在体内诱导动物和人类造血细胞的相对缓慢动员。这为详细研究造血干细胞和祖细胞迁移动力学提供了时间框架。
小鼠每天腹腔注射 Flt3 配体(10μg/天)3、5、7 和 10 天。通过集落形成单位粒细胞/单核细胞和鹅卵石区域形成细胞测定研究造血干细胞和祖细胞的动员情况。通过将 1.5x10(6)Flt3 配体动员的外周血单核细胞移植到致死性照射(9.5Gy)的受体中,研究动员外周血单核细胞的放射保护能力。
从第 3 天开始检测到造血祖细胞动员,并且持续给予 Flt3 配体可导致动员的祖细胞持续增加。与 5 天的 Flt3 配体给药相比,10 天的 Flt3 配体给药导致第 4 周时鹅卵石区域形成细胞增加 5.5 倍,第 5 周时增加 5.0 倍。此外,5 天的 Flt3 配体给药动员的外周血单核细胞不能放射保护致死性照射的受体,而 10 天的 Flt3-Ligand 给药动员的外周血单核细胞可使受体获得 100%的放射保护,并具有显著的多谱系供体嵌合体。与单独给予 Flt3 配体或白细胞介素-8 相比,白细胞介素-8 和 Flt3 配体的联合给药可在第 3 天和第 5 天协同增强造血干细胞和祖细胞的动员。
这些结果表明,造血干细胞和祖细胞对 Flt3 配体的反应存在不同的动员动力学,导致第 5 天优先动员造血祖细胞,第 10 天动员造血干细胞。